References

Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors

2026 · External reference

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

10.1111/jth.13140 · 2015 · External reference

10.1111/j.1538-7836.2005.01204.x

10.1111/j.1538-7836.2005.01204.x · 2005 · External reference

Mechanisms of adverse effects of anti-VEGF therapy for cancer

10.1038/sj.bjc.6603813 · 2007 · External reference

Weibel-Palade bodies orchestrate pericytes during angiogenesis

10.1161/atvbaha.119.313021 · 2019 · External reference

Exocytosis of Weibel-Palade bodies: how to unpack a vascular emergency kit

10.1111/jth.14322 · 2019 · External reference

Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding

10.1007/s11239-025-03151-w · 2026 · External reference

Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin

10.1002/cncr.33337 · 2021 · External reference

Retrospective study of bleeding risk with concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor and anticoagulation

10.1002/onco.13897 · 2021 · External reference

Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents

10.1053/j.seminoncol.2023.05.002 · 2023 · External reference

Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study

2022 · External reference

Tranexamic acid in bleeding management of advanced cancer in palliative care: a systematic review

2026 · External reference

Integrated cardio-oncology service

10.15420/cfr.2025.44 · 2026 · External reference